Every material Form 8-K Bicara Therapeutics Inc. has filed with the SEC since July 28, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Bicara Therapeutics reported a third-quarter 2026 net loss of $71.2 million, nearly double the $36.3 million loss a year earlier, as research and development and general and administrative costs rose for its pivotal trial and commercial preparation. The company said its $442.3 million in cash and marketable securities should fund operations into the first half of 2029, and it reiterated that topline interim results from the FORTIFI-HN01 pivotal trial are expected in mid-2027.
Net loss was $71.2 million for the quarter ended September 30, 2026, versus $36.3 million a year earlier.
Research and development expenses rose to $56.5 million from $33.0 million; general and administrative expenses rose to $19.2 million from $7.7 million.
Cash, cash equivalents and marketable securities were $442.3 million at September 30, 2026, which the company expects to fund operations into the first half of 2029.
Topline interim results from the FORTIFI-HN01 pivotal trial are expected in mid-2027.
Bicara Therapeutics entered a sub-sublease with Wayfair LLC on August 21, 2026, for about 35,090 square feet of office space at 10 St. James Avenue, Boston, to serve as its new corporate headquarters. Base rent is $105,279 per month, payable nine months after the commencement date, which is the later of October 1, 2026 and full execution of a landlord consent.
Premises: approximately 35,090 square feet at 10 St. James Avenue, Boston, Massachusetts
Base rent of $105,279 per month, starting nine months after the commencement date
Security deposit of $210,540 paid at signing
Sublease term ends on the earlier of September 30, 2028 or earlier termination under its terms
Bicara Therapeutics said Ryan Cohlhepp, its President and Chief Operating Officer, will succeed Claire Mazumdar as Chief Executive Officer effective January 1, 2027, and Jenn Larson will become Chief Financial Officer effective August 12, 2026. The company also reported a second quarter 2026 net loss of $55.4 million, up from $27.4 million a year earlier, while cash, cash equivalents and marketable securities rose to $497.3 million.
Ryan Cohlhepp will become CEO effective January 1, 2027; Claire Mazumdar will become Vice Chair of the Board and Strategic Advisor.
Jenn Larson, CPA, appointed Chief Financial Officer effective August 12, 2026, succeeding Ivan Hyep.
Q2 2026 net loss was $55.4 million versus $27.4 million in Q2 2025; R&D expenses were $45.8 million versus $24.8 million.
Cash, cash equivalents and marketable securities were $497.3 million at June 30, 2026, which the company expects to fund operations into the first half of 2029.
Bicara Therapeutics appointed Jeremy Bender, Ph.D. and Christy Oliger to its Board of Directors, effective July 28, 2026, increasing the Board from nine to ten members. Director Kiran Mazumdar-Shaw resigned from the Board and its Nominating and Corporate Governance Committee on the same effective date, and the filing says her decision was not the result of any disagreement with the Company. The Board also formed a Launch Readiness Committee to advise management on commercialization strategy for ficerafusp alfa.
Jeremy Bender, Ph.D. appointed as a Class I director, serving until the 2028 annual meeting; joins the Audit Committee, replacing Carolyn Ng, Ph.D.
Christy Oliger appointed as a Class II director, serving until the 2029 annual meeting; joins the Nominating and Corporate Governance Committee.
Kiran Mazumdar-Shaw resigned from the Board and Nominating and Corporate Governance Committee, effective July 28, 2026.
Each non-employee director receives an initial option award of 38,950 shares of common stock; the new Launch Readiness Committee is chaired by Kate Haviland.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Bicara Therapeutics Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →